Search

Your search keyword '"Kreuter, Michael"' showing total 1,422 results
Start Over Author "Kreuter, Michael"
1,422 results on '"Kreuter, Michael"'

1. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Author

Khanna, Dinesh, Maher, Toby, Volkmann, Elizabeth, Allanore, Yannick, Smith, Vanessa, Assassi, Shervin, Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Kuwana, Masataka, Stock, Christian, Alves, Margarida, Sambevski, Steven, and Denton, Christopher

Subjects
Autoimmune Diseases, Pulmonary Fibrosis, Scleroderma, Systemic, Therapeutics, Humans, Fibrosis, Lung Diseases, Interstitial, Risk Factors, Scleroderma, Systemic
Abstract

OBJECTIVE: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC. METHODS: The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of ≥10% extent on high-resolution CT. The rate of decline in FVC over 52 weeks was analysed in all subjects and in those with early SSc (

Published
2023

2. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Author

Volkmann, Elizabeth, Kreuter, Michael, Hoffmann-Vold, Anna, Wijsenbeek, Marlies, Smith, Vanessa, Khanna, Dinesh, Denton, Christopher, Wuyts, Wim, Miede, Corinna, Alves, Margarida, Sambevski, Steven, and Allanore, Yannick

Subjects
connective tissue diseases, nintedanib, systemic scleroderma, vital capacity, Humans, Cough, Lung Diseases, Interstitial, Vital Capacity, Dyspnea, Scleroderma, Systemic, Disease Progression, Treatment Outcome
Abstract

OBJECTIVE: The aim of these analyses was to investigate the rate of decline in forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSCIS trial. METHODS: Patients in the SENSCIS trial were randomized to receive nintedanib or placebo. Subgroups with and without cough or dyspnoea at baseline were defined by responses to the St Georges Respiratory Questionnaire. RESULTS: At baseline, 114/575 patients (19.8%) did not have cough and 172/574 patients (30.0%) did not have dyspnoea. In the placebo group, the rate of FVC decline over 52 weeks was similar in patients with and without cough (-95.6 and -83.4 mL/year, respectively) or dyspnoea (-95.8 and -87.7 mL/year, respectively). The effect of nintedanib vs placebo on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough [difference: 74.4 (95% CI -11.1, 159.8) vs 31.5 (-11.1, 74.1)] and without than with dyspnoea [79.8 (9.8, 149.7) vs 25.7 (-19.9, 71.3)], but interaction P-values did not indicate heterogeneity in the treatment effect between these subgroups (P = 0.38 and P = 0.20, respectively). CONCLUSION: In the placebo group of the SENSCIS trial, the rate of FVC decline was similar irrespective of the presence of cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough or dyspnoea at baseline, but no statistically significant heterogeneity was observed between the subgroups. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.

Published
2022

7. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

Author

Anderson, Adam, Morgenthau, Adam, Gaser, Adrian, Vizel, Alexander, Speranskaya, Alexandra, Gerke, Alicia, Goksel, Altinisik, Undurraga, Alvaro, Sharma, Amita, Oh, Andrea, Leung, Ann, Larici, Anna Rita, Prasse, Antje, Mazzei, Antonietta, Morais, Antonio, Bhalla, Ashu, Del Rio, Belen, Jankharia, Bhavin, Elicker, Brett, Pereira, Carlos, Biegelman-Aubry, Catherine, White, Charles, Ravaglia, Claudia, Hsia, Connie, Schaefer-Prokop, Cornelia, Launay, David, Talwar, Deepak, Castillo, Diego, Patel, Divya, Israel-Biet, Dominique, Valeyre, Dominique, Britt, Edward James, Bargagli, Elena, Bendstrup, Elisabeth, Crouser, Elliott, Nossent, Esther, Shmelev, Eugeny, Porquera, Eva Carmona, Bonella, Francesco, Cohen-Aubart, Fleur, Jeny, Florence, Ferrara, Giovanni, Jin, Gong Yong, Robbie, Hasti, Prosch, Helmut, Sumikawa, Hiromitsu, Ling-Pei, Ho, Lee, Ho Yun, Strambu, Irina, Buendia-Roldan, Ivette, Grutters, Jan, Ryu, Jay, Swigris, Jeff, Miedema, Jelle, Goo, Jin Mo, Barnett, Joseph, Verschakelen, Johny, Goldin, Jonathan, Seo, Joon Beom, Enghelmayer, Juan, Mana, Juan, Behr, Juergen, Patterson, Karen, Antoniou, Katerina, Brown, Kevin, Fujimoto, Kiminori, Savale, Laurent, Maier, Lisa, Richeldi, Luca, Neto, Manuel Lessa Ribeiro, Humbert, Marc, Judson, Marc, Veltkamp, Marcel, Wilsher, Margaret, Molina, Maria, Otaola, Maria, Revel, Marie-Pierre, Silva, Mario, Drent, Marjolein, Schiebler, Mark, Wijsenbeek-Lourens, Marlies, Bonifazi, Martina, Remy-Jardin, Martine, Koslow, Matthew, Balter, Meyer, Kreuter, Michael, Thillai, Muhunthan, Hamzeh, Nabeel, Chaudhuri, Nazia, Mogulkoc, Nesrin, Todd, Nevins, Screaton, Nick, Goh, Nicole, Shah, Nirav, Obi, Ogugua, Shlobin, Oksana, Baranova, Olga, Bresser, Paul, Rottoli, Paula, Brillet, Pierre-Yves, Said-Hartley, Qonita, Borie, Raphael, Mostard, Remy, van Zyl-smit, Richard, Kairalla, Ronaldo, Egashira, Ryoko, Boussouar, Samia, Lee, Sang Min, Bhalla, Sanjeev, Tomassetti, Sara, Quadrelli, Silvia, Hart, Simon P, Danoff, Sonye, Rajan, Sujeet, Choi, Sun Mi, Copley, Susan, Kim, Tae Jung, Johkoh, Takeshi, Corte, Tamera, McLoud, Theresa, Wessendorf, Thomas, Alfaro, Tiago, Arai, Toru, Costabel, Ulrich, Vicens-Zygmunt, Vanesa, Poletti, Venerino, Cottin, Vincent, Vucinic, Violeta, Wuyts, Wim, van Es, Wouter, Jeong, Yeon Joo, Inoue, Yoshikazu, Desai, Sujal R, Sivarasan, Nishanth, Johannson, Kerri A, George, Peter M, Culver, Daniel A, Devaraj, Anand, Lynch, David A, Milne, David, Renzoni, Elisabetta, Nunes, Hilario, Sverzellati, Nicola, Spagnolo, Paolo, Baughman, Robert P, Yadav, Ruchi, Piciucchi, Sara, Walsh, Simon L F, Kouranos, Vasileios, and Wells, Athol U

Published
2024
Full Text
View/download PDF

10. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis

Author

Moinzadeh, Pia, Bonella, Francesco, Oberste, Max, Weliwitage, Jithmi, Blank, Nobert, Riemekasten, Gabriela, Müller-Ladner, Ulf, Henes, Jörg, Siegert, Elise, Günther, Claudia, Kötter, Ina, Pfeiffer, Christiane, Schmalzing, Marc, Zeidler, Gabriele, Korsten, Peter, Susok, Laura, Juche, Aaron, Worm, Margitta, Jandova, Ilona, Ehrchen, Jan, Sunderkötter, Cord, Keyßer, Gernot, Ramming, Andreas, Schmeiser, Tim, Kreuter, Alexander, Lorenz, Hanns-Martin, Hunzelmann, Nicolas, and Kreuter, Michael

Published
2024
Full Text
View/download PDF

11. Early Detection of Lung Cancer Using Small RNAs

Author

Sikosek, Tobias, Horos, Rastislav, Trudzinski, Franziska, Jehn, Julia, Frank, Maurice, Rajakumar, Timothy, Klotz, Laura V., Mercaldo, Nathaniel, Kahraman, Mustafa, Heuvelman, Marco, Taha, Yasser, Gerwing, Jennifer, Skottke, Jasmin, Daniel-Moreno, Alberto, Sanchez-Delgado, Marta, Bender, Sophie, Rudolf, Christina, Hinkfoth, Franziska, Tikk, Kaja, Schenz, Judith, Weigand, Markus A., Feindt, Peter, Schumann, Christian, Christopoulos, Petros, Winter, Hauke, Kreuter, Michael, Schneider, Marc A., Muley, Thomas, Walterspacher, Stephan, Schuler, Martin, Darwiche, Kaid, Taube, Christian, Hegedus, Balazs, Rabe, Klaus F., Rieger-Christ, Kimberly, Jacobsen, Francine L., Aigner, Clemens, Reck, Martin, Bankier, Alexander A., Sharma, Amita, and Steinkraus, Bruno R.

Published
2023
Full Text
View/download PDF

12. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Author

Kreuter, Michael, Lee, Joyce S, Tzouvelekis, Argyrios, Oldham, Justin M, Molyneaux, Philip L, Weycker, Derek, Atwood, Mark, Kirchgaessler, Klaus-Uwe, and Maher, Toby M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Lung, Clinical Trials and Supportive Activities, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Biomarkers, Female, Humans, Idiopathic Pulmonary Fibrosis, Male, Middle Aged, Monocytes, Prognosis, Retrospective Studies, Risk Assessment, prognosis, pulmonary fibrosis, biomarkers, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between monocyte count and prognosis in patients with IPF. Methods: This retrospective pooled analysis included patients (active and placebo arms) from the following four phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 and NCT00287716), and INSPIRE (NCT00075998). Outcomes included IPF progression (≥10% absolute decline in FVC% predicted, ≥50 m decline in 6-minute-walk distance, or death), all-cause hospitalization, and all-cause mortality over 1 year. The relationship between monocyte count (defined as time-dependent) and outcomes was assessed using bivariate and multivariable models. Measurements and Main Results: This analysis included 2,067 patients stratified by monocyte count (at baseline:

Published
2021

13. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Author

Denkinger, Claudia M., Janssen, Maike, Schäkel, Ulrike, Gall, Julia, Leo, Albrecht, Stelmach, Patrick, Weber, Stefan F., Krisam, Johannes, Baumann, Lukas, Stermann, Jacek, Merle, Uta, Weigand, Markus A., Nusshag, Christian, Bullinger, Lars, Schrezenmeier, Jens-Florian, Bornhäuser, Martin, Alakel, Nael, Witzke, Oliver, Wolf, Timo, Vehreschild, Maria J. G. T., Schmiedel, Stefan, Addo, Marylyn M., Herth, Felix, Kreuter, Michael, Tepasse, Phil-Robin, Hertenstein, Bernd, Hänel, Mathias, Morgner, Anke, Kiehl, Michael, Hopfer, Olaf, Wattad, Mohammad-Amen, Schimanski, Carl C., Celik, Cihan, Pohle, Thorsten, Ruhe, Matthias, Kern, Winfried V., Schmitt, Anita, Lorenz, Hanns-Martin, Souto-Carneiro, Margarida, Gaeddert, Mary, Halama, Niels, Meuer, Stefan, Kräusslich, Hans-Georg, Müller, Barbara, Schnitzler, Paul, Parthé, Sylvia, Bartenschlager, Ralf, Gronkowski, Martina, Klemmer, Jennifer, Schmitt, Michael, Dreger, Peter, Kriegsmann, Katharina, Schlenk, Richard F., and Müller-Tidow, Carsten

Published
2023
Full Text
View/download PDF

15. Klinische Diagnostik

Author

Kirsten, Detlef, Kreuter, Michael, Herth, Felix JF, Costabel, Ulrich, Kreuter, Michael, editor, Costabel, Ulrich, editor, Herth, Felix JF, editor, and Kirsten, Detlef, editor

Published
2022
Full Text
View/download PDF

16. Pulmonale Alveolarproteinose

Author

Bonella, Francesco, Lachmann, Nico, Kreuter, Michael, Costabel, Ulrich, Kreuter, Michael, editor, Costabel, Ulrich, editor, Herth, Felix JF, editor, and Kirsten, Detlef, editor

Published
2022
Full Text
View/download PDF

17. Birt-Hogg-Dubé-Syndrom

Author

Brunnemer, Eva, Kreuter, Michael, Kreuter, Michael, editor, Costabel, Ulrich, editor, Herth, Felix JF, editor, and Kirsten, Detlef, editor

Published
2022
Full Text
View/download PDF

19. Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial.

Author

Maher, Toby, Mayes, Maureen, Kreuter, Michael, Volkmann, Elizabeth, Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, and Raghu, Ganesh

Subjects
Adult, Aged, Disease Progression, Double-Blind Method, Female, Humans, Indoles, Lung, Lung Diseases, Interstitial, Male, Middle Aged, Protein Kinase Inhibitors, Scleroderma, Systemic, Treatment Outcome
Abstract

OBJECTIVE: In the SENSCIS trial in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categorical changes in FVC and other measures of ILD progression. METHODS: In post hoc analyses, we assessed the proportions of subjects with categorical changes in FVC % predicted at week 52 and the time to absolute decline in FVC of ≥5% predicted or death and absolute decline in FVC of ≥10% predicted or death. RESULTS: A total of 288 subjects received nintedanib and 288 subjects received placebo. At week 52, in subjects treated with nintedanib and placebo, respectively, 55.7% and 66.3% had any decline in FVC % predicted, 13.6% and 20.1% had a decline in FVC of >5% to ≤10% predicted, and 3.5% and 5.2% had a decline in FVC of >10% to ≤15% predicted; 34.5% and 43.8% had a decrease in FVC of ≥3.3% predicted (proposed minimal clinically important difference [MCID] for worsening of FVC), while 23.0% and 14.9% had an increase in FVC of ≥3.0% predicted (proposed MCID for improvement in FVC). Over 52 weeks, the hazard ratio (HR) for an absolute decline in FVC of ≥5% predicted or death with nintedanib versus placebo was 0.83 (95% confidence interval [95% CI] 0.66-1.06) (P = 0.14), and the HR for an absolute decline in FVC of ≥10% predicted was 0.64 (95% CI 0.43-0.95) (P = 0.029). CONCLUSION: These results suggest that nintedanib has a clinically relevant benefit on the progression of SSc-ILD.

Published
2021

20. Natural variability in the disease course of SSc-ILD: implications for treatment.

Author

Vonk, Madelon, Walker, Ulrich, Volkmann, Elizabeth, Kreuter, Michael, Johnson, Sindhu, and Allanore, Yannick

Subjects
Humans, Lung, Lung Diseases, Interstitial, Risk Factors, Scleroderma, Systemic, Vital Capacity
Abstract

Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies, we assessed definitions and patterns of progression, risk factors for progression, and implications for treatment. SSc-ILD progression was commonly defined as exceeding specific thresholds of lung function worsening and/or increasing radiographic involvement. One definition used in several studies is decline in forced vital capacity (FVC) of ≥10%, or ≥5-10% plus a decline in diffusing capacity of the lung for carbon monoxide ≥15%. Based on these criteria, 20-30% of patients in observational cohorts develop progressive ILD, starting early in the disease course and progressing at a highly variable rate.Risk factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power. Whilst the variability of the disease course in SSc-ILD makes risk stratification of patients challenging, the decision to initiate, change or stop treatment should be based on a combination of the current disease state and the speed of progression.

Published
2021

22. Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry

Author

Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, Höger, Philipp, Somogyi, Vivien, Lederer, Christoph, Markart, Philipp, and Kreuter, Michael

Published
2024
Full Text
View/download PDF

23. miR-Blood – a small RNA atlas of human blood components

Author

Jehn, Julia, Trudzinski, Franziska, Horos, Rastislav, Schenz, Judith, Uhle, Florian, Weigand, Markus A., Frank, Maurice, Kahraman, Mustafa, Heuvelman, Marco, Sikosek, Tobias, Rajakumar, Timothy, Gerwing, Jennifer, Skottke, Jasmin, Daniel-Moreno, Alberto, Rudolf, Christina, Hinkfoth, Franziska, Tikk, Kaja, Christopoulos, Petros, Klotz, Laura V., Winter, Hauke, Kreuter, Michael, and Steinkraus, Bruno R.

Published
2024
Full Text
View/download PDF

24. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry

Author

Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, Höger, Philipp, Somogyi, Vivien, Lederer, Christoph, Markart, Philipp, and Kreuter, Michael

Published
2024
Full Text
View/download PDF

25. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Study

Author

Lancaster, Lisa, primary, Cottin, Vincent, additional, Ramaswamy, Murali, additional, Wuyts, Wim A., additional, Jenkins, R. Gisli, additional, Scholand, Mary Beth, additional, Kreuter, Michael, additional, Valenzuela, Claudia, additional, Ryerson, Christopher J, additional, Goldin, Jonathan, additional, Kim, Grace Hyun J, additional, Jurek, Marzena, additional, Decaris, Martin, additional, Clark, Annie, additional, Turner, Scott, additional, Barnes, Chris N., additional, Achneck, Hardean E, additional, Cosgrove, Gregory, additional, Lefebvre, Éric A, additional, and Flaherty, Kevin R., additional

Published
2024
Full Text
View/download PDF

26. Lung Fibrosis Is Linked to Increased Endothelial Cell Activation and Dysfunctional Vascular Barrier Integrity

Author

Fließer, Elisabeth, primary, Jandl, Katharina, additional, Lins, Thomas, additional, Birnhuber, Anna, additional, Valzano, Francesco, additional, Kolb, Dagmar, additional, Foris, Vasile, additional, Heinemann, Akos, additional, Olschewski, Horst, additional, Evermann, Matthias, additional, Hoetzenecker, Konrad, additional, Kreuter, Michael, additional, Voelkel, Norbert F, additional, Marsh, Leigh M, additional, Wygrecka, Malgorzata, additional, and Kwapiszewska, Grazyna, additional

Published
2024
Full Text
View/download PDF

27. Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World.

Author

Polke, Markus, Kondoh, Yasuhiro, Wijsenbeek, Marlies, Cottin, Vincent, Walsh, Simon, Collard, Harold, Chaudhuri, Nazia, Avdeev, Sergey, Behr, Jürgen, Calligaro, Gregory, Corte, Tamera, Flaherty, Kevin, Funke-Chambour, Manuela, Kolb, Martin, Krisam, Johannes, Maher, Toby, Molina Molina, Maria, Morais, Antonio, Moor, Catharina, Morisset, Julie, Pereira, Carlos, Quadrelli, Silvia, Selman, Moises, Tzouvelekis, Argyrios, Valenzuela, Claudia, Vancheri, Carlo, Vicens-Zygmunt, Vanesa, Wälscher, Julia, Wuyts, Wim, Bendstrup, Elisabeth, and Kreuter, Michael

Subjects
acute exacerbation, idiopathic pulmonary fibrosis, non-specialised ILD centres, pulmonologists, questionnaire, specialised ILD centres
Abstract

Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe complication associated with a high mortality. However, evidence and guidance on management is sparse. The aim of this international survey was to assess differences in prevention, diagnostic and treatment strategies for AE-IPF in specialised and non-specialised ILD centres worldwide. Material and Methods: Pulmonologists working in specialised and non-specialised ILD centres were invited to participate in a survey designed by an international expert panel. Responses were evaluated in respect to the physicians institutions. Results: Three hundred and two (65%) of the respondents worked in a specialised ILD centre, 134 (29%) in a non-specialised pulmonology centre. Similarities were frequent with regards to diagnostic methods including radiology and screening for infection, treatment with corticosteroids, use of high-flow oxygen and non-invasive ventilation in critical ill patients and palliative strategies. However, differences were significant in terms of the use of KL-6 and pathogen testing in urine, treatments with cyclosporine and recombinant thrombomodulin, extracorporeal membrane oxygenation in critical ill patients as well as antacid medication and anaesthesia measures as preventive methods. Conclusion: Despite the absence of recommendations, approaches to the prevention, diagnosis and treatment of AE-IPF are comparable in specialised and non-specialised ILD centres, yet certain differences in the managements of AE-IPF exist. Clinical trials and guidelines are needed to improve patient care and prognosis in AE-IPF.

Published
2021

30. Home monitoring in interstitial lung diseases

Author

Wijsenbeek, Marlies S, Moor, Catharina C, Johannson, Kerri A, Jackson, Peter D, Khor, Yet H, Kondoh, Yasuhiro, Rajan, Sujeet K, Tabaj, Gabriela C, Varela, Brenda E, van der Wal, Pieter, van Zyl-Smit, Richard N, Kreuter, Michael, and Maher, Toby M

Published
2023
Full Text
View/download PDF

32. Diagnostic Potential of Supplemental Static and Dynamic68Ga-FAPI-46 PET for Primary18F-FDG–Negative Pulmonary Lesions

Author

Röhrich, Manuel, primary, Daum, Johanna, additional, Gutjahr, Ewgenija, additional, Spektor, Anna-Maria, additional, Glatting, Frederik M., additional, Sahin, Yasemin Aylin, additional, Buchholz, Hans Georg, additional, Hoppner, Jorge, additional, Schroeter, Cathrin, additional, Mavriopoulou, Eleni, additional, Schlamp, Kai, additional, Grott, Matthias, additional, Eichhorn, Florian, additional, Heußel, Claus Peter, additional, Kauczor, Hans Ulrich, additional, Kreuter, Michael, additional, Giesel, Frederik, additional, Schreckenberger, Mathias, additional, Winter, Hauke, additional, and Haberkorn, Uwe, additional

Published
2024
Full Text
View/download PDF

35. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

Author

Kawano-Dourado, Leticia, primary, Kulkarni, Tejaswini, additional, Ryerson, Christopher J, additional, Rivera-Ortega, Pilar, additional, Baldi, Bruno Guedes, additional, Chaudhuri, Nazia, additional, Funke-Chambour, Manuela, additional, Hoffmann-Vold, Anna-Maria, additional, Johannson, Kerri A, additional, Khor, Yet Hong, additional, Montesi, Sydney B, additional, Piccari, Lucilla, additional, Prosch, Helmut, additional, Molina-Molina, María, additional, Sellares Torres, Jacobo, additional, Bauer-Ventura, Iazsmin, additional, Rajan, Sujeet, additional, Jacob, Joseph, additional, Richards, Duncan, additional, Spencer, Lisa G, additional, Wendelberger, Barbara, additional, Jensen, Tom, additional, Quintana, Melanie, additional, Kreuter, Michael, additional, Gordon, Anthony C, additional, Martinez, Fernando J, additional, Kaminski, Naftali, additional, Cornelius, Victoria, additional, Lewis, Roger, additional, Adams, Wendy, additional, and Jenkins, Gisli, additional

Published
2024
Full Text
View/download PDF

37. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Author

Raghu, Ganesh, Hamblin, Mark J., Brown, A. Whitney, Golden, Jeffrey A., Ho, Lawrence A., Wijsenbeek, Marlies S., Vasakova, Martina, Pesci, Alberto, Antin-Ozerkis, Danielle E., Meyer, Keith C., Kreuter, Michael, Burgess, Tracy, Kamath, Nikhil, Donaldson, Francis, and Richeldi, Luca

Published
2022
Full Text
View/download PDF

50. Inadequate Palliative Care in Lung Disease

Author

Villalobos, Matthias, Kreuter, Michael, Rounds, Sharon I. S., Series Editor, Dixon, Anne, Series Editor, Schnapp, Lynn M., Series Editor, Lindell, Kathleen O., editor, and Danoff, Sonye K., editor

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results